Born 1956. Ph.D. from Karolinska Institutet in Stockholm. Board member since 2016.
Other appointments: Currently serves as Industry Executive at Avista Capital Partners.
Previous appointments: Extensive international background in the life science industry, from both R&D and sales and marketing. Håkan has served as a Member of the Board of Directors of several international life science companies including Alere, Coloplast, Danisco and Lundbeck. Between 2001 and 2007, Håkan Björklund also served as member of the Board of Directors for Biovitrum.
Born 1954. BSc Hons Pharmacology from Bath University UK. Board member since 2014.
Other appointments: Non executive Chairman of the Board, Enyo SA and Lysogene SA. Member of the Board of Directors, Obseva SA.
Previous appointments: Senior Advisor, Biopharmaceutical Team of Frazier Healthcare. Chair of the Board of Directors, Genable Therapeutics. Non-Executive Board Director, Silence Therapeutics plc. and Clavis Pharma. Head of Transaction and Alliance Management at GlaxoSmithKline (GSK).
Born 1965. BA Princeton University and MBA from Harvard Business School. Board member since 2012.
Other appointments: CEO of OxThera AB. Member of the board for Pennsylvania Life Sciences Association and Marine Corps Scholarship Foundation.
Previous appointments: Executive Vice President of BTG Plc, Founder and previously CEO of Acureon Pharmaceuticals, President and CEO of Hydrabiosciences Inc., VP Europe for Chiron's Biopharmaceutical Division and General Manager for PathoGenesis Europe. Prior to Chiron/PathoGenesis a variety of US sales and marketing roles at Abbott Laboratories Diagnostic Division
Born 1955. MBA from Stockholm School of Economics. Board member since 2010
Other appointments: Member of the management team and Senior Advisor at Patricia Industries (division of Investor AB). Chairman of the board of Fastighets AB Tingshuset 13, board member of Vectura Fastigheter AB, HI3G, Chalmers Ventures, Bonesupport AB, and deputy board member of Mölnlycke Health Care.
Previous appointments: Chairman of the Board of Vectura Fastigheter AB, CEO in b-business partners and Emerging Technologies AB. Board member of SAAB AB, IBX Group AB and Gambro Holding AB.
Born 1970. MSc from Stockholm School of Economics. Board member since 2011.
Other appointments: CFO at Investor AB. Board member of SEB.
Previous appointments: CFO of Hallvarsson & Halvarsson, Vice President at Investor AB and financial analyst at Goldman Sachs. Board member of Aleris and Mölnlycke Health Care.
Born 1958. Pharmacist, Utrecht University. Board member since 2011.
Other appointments: Chairman of the Board of Directors of Asceneuron, Switzerland, Interna, The Netherlands and Complix, Belgium. Member of the Board of Directors of Hansa Medical and Wilson Therapeutics, Sweden, Therachon, Switzerland as well as of the Dutch Top Sector Life Sciences & Health, The Netherlands. Advisor to various organisations in Life Sciences & Health
Previous appointments: CEO of Prosensa, Director of the Supervisory Board of Prosensa, Board member of Top Institute Pharma, Chairman of Dutch Association of the Innovative Pharmaceutical Industry, Nefarma. Various senior management positions within previous Organon and Genzyme.
Born 1961. MD and PhD from the University of Gothenburg, Sweden. Board member since 2018.
Other appointments: Currently serves as associate professor of surgery and is serving as Chief Development Officer at Ixaltis SA since 2016. Member of the Board of Directors of Follicum AB and PledPharma AB
Previous appointments: Board member of the Swedish American Chamber of Commerce New York. Head of the Established Products Group at Janssen Pharmaceuticals 2014–2016. Leading the development of a novel diabetes medicine at Bristol Myers Squibb (BMS) in the US. Head of Medical Affairs for the Intercontinental region. 2000–2007.
Born 1963. BSc Hons Chemistry from Coventry University, UK. Board member since 2018.
Other appointments: Director and sole employee in U-R-NOT Ltd., through which Mr Allsop offers advisory services to the pharma industry.
Previous appointments: More than 30 years’ of experience from research as well as marketing within the pharmaceuticals and health care industries. International experience from the pharmaceutical and biotechnology industry and a commercial and general management background. Until January 2018, Head of International in Amicus Therapeutics Ltd. A number of senior positions in Biogen 1998–2015.